Sugi Predict

Sugi Predict / Compounds / SCHEMBL960443

SCHEMBL960443

SCHEMBL960443

COC(=O)c1cccc([N+](=O)[O-])c1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.53
▸ ALDH1A1 P00352 8/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ MAPT P10636 4/20 0.48
▸ MAPK1 P28482 4/20 0.48
▸ KDM4E B2RXH2 2/20 0.47
▸ PKM P14618 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ GLA P06280 1/20 0.47
▸ LMNA P02545 2/20 0.46
▸ POLB P06746 2/20 0.46
▸ TDP1 Q9NUW8 2/20 0.45
▸ CTSD P07339 1/20 0.45
▸ ABCC4 O15439 1/20 0.45
▸ PLIN1 O60240 1/20 0.45
▸ CACNA1F O60840 1/20 0.45
▸ GMNN O75496 1/20 0.45
▸ KCNK2 O95069 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22009916 0.85 SIRT6 (0.47) TSHRALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL14933431 0.83 TSHR (0.56) TSHRALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL307312 0.83 TSHR (0.70) TSHRALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL29959661 0.83 TSHR (0.70) TSHRALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL31187277 0.83 TSHR (0.45) TSHRALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL8991983 0.83 ALDH1A1 (0.54) TSHRALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL195311 0.83 ALDH1A1 (0.62) TSHRALDH1A1SMN1; SMN2KMT2AMAPT
SCHEMBL50994 0.82 TSHR (0.54) TSHRALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL7369896 0.82 TSHR (0.54) TSHRALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL391265 0.82 GPR35 (0.58) TSHRALDH1A1SMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119798108-A Preparation method of inner-ring profenofos and intermediate thereof in micro-channel 福州大学 2025-04-11 — — CN claimed
CN-113717053-A Synthesis method of key intermediate of tyrosine kinase inhibitor 合肥利夫生物科技有限公司 2021-11-30 — — CN claimed
US-12606533-B2 3-phenylpropylamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2026-04-21 — — US disclosed
EP-4709712-A1 GSK3A INHIBITORS AND METHODS OF USE THEREOF Blueprint Medicines Corporation (US) 2026-03-18 — — EP disclosed
US-12497382-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2025-12-16 — — US disclosed
US-20250353824-A1 3-PHENYLPROPYLAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-11-20 — — US disclosed
EP-4610251-A1 HEPTAFLUOROISOPROPYL-CONTAINING BISAMIDE COMPOUND AND INTERMEDIATE COMPOUND THEREOF, AND PREPARATION METHODS THEREFOR AND USE THEREOF Zhejiang Udragon Pesticides And Chemicals Co., Ltd. (CN) 2025-09-03 — — EP disclosed
US-12331026-B2 Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors NIKANG THERAPEUTICS, INC. (US) 2025-06-17 — — US disclosed
CN-119874674-A GLP-1R modulating compounds 吉利德科学公司 2025-04-25 — — CN disclosed
CN-119798108-A Preparation method of inner-ring profenofos and intermediate thereof in micro-channel 福州大学 2025-04-11 — — CN disclosed
WO-2025072462-A1 SULFONAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2025-04-03 — — WO disclosed
US-20100004233-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-01-07 — — US disclosed
US-20100004233-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-01-07 — — US disclosed
US-20090298815-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds NOVARTIS AG (CH) 2009-12-03 — — US disclosed
US-20090298815-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds NOVARTIS AG (CH) 2009-12-03 — — US disclosed
US-20090298815-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds NOVARTIS AG (CH) 2009-12-03 — — US disclosed
WO-2009137391-A2 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-11-12 — — WO disclosed
WO-2009137391-A2 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-11-12 — — WO disclosed
EP-1982982-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-10-22 — — EP disclosed
US-5543550-A NITRATING ALKYL ESTER OF 3-FLUOROBENZOIC ACID DISSOLVED IN SOLVENT-FREE SULFURIC ACID, THEN ADDING WATER, SEPARATION, HYDROLYSIS, PRESSURIZED CATALYTIC HYDROGENATION OF THE NITRATED ACID HOECHST AKTIENGESELLSCHAFT (DE) 1996-08-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353824-A1 3-PHENYLPROPYLAMINE DERIVATIVE SF1, SF3A1, SFXN1 TSHR 1698/4885ALDH1A1 358/4885SMN1; SMN2 1764/4885
US-12331026-B2 Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors CDK2, CCNK, CCNI TSHR 3290/4885ALDH1A1 3620/4885SMN1; SMN2 1215/4885
US-12606533-B2 3-phenylpropylamine derivative SF3A1, SF1, HTR1D TSHR 1117/4885ALDH1A1 357/4885SMN1; SMN2 707/4885
US-20100004233-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 TSHR 4227/4885ALDH1A1 452/4885SMN1; SMN2 3053/4885
US-20090298815-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds STS, TST, TPST2 TSHR 1140/4885ALDH1A1 915/4885SMN1; SMN2 2314/4885
US-12497382-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 TSHR 120/4885ALDH1A1 3556/4885SMN1; SMN2 1956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.